Eikon Therapeutics(NASDAQ) EIKN

Eikon Therapeutics makes new medicines to treat cancer. It uses special cameras to watch protein movement in cells. This helps scientists find better ways to fight serious diseases.

What is Eikon Building?

• Immune System Activators: Compounds like EIK1001 designed to trigger the body's natural defenses against advanced skin and lung cancers; currently in Phase 2/3 trials, which are large studies comparing new drugs to standard treatments.
• DNA Repair Blockers: Targeted inhibitors known as EIK1003 and EIK1004 that prevent cancer cells from repairing genetic damage; currently in Phase 1/2 trials, which are early studies testing safety and finding the right dose in humans.
• Synthetic Lethality Agents: Internally discovered molecules like EIK1005 that exploit genetic weaknesses in tumors; these focus on specific cancers that have trouble repairing their own DNA.
• Hormone Signal Blockers: Experimental treatments such as EIK1006 that aim to stop signals that help prostate cancer grow and spread.

Strategic Partnerships and Progress

• In-licensed global rights for the immunotherapy candidate EIK1001 from Seven and Eight Biotherapeutics and Superb Wisdom Limited.
• Partnered with Impact Therapeutics to obtain exclusive rights to develop selective DNA repair inhibitors outside of Greater China.
• Advanced the internally discovered EIK1005 program from early research to human clinical testing in less than 18 months.
• Initiated site selection for a global registrational study of EIK1001 to treat patients with stage 4 lung cancer.

Tracking Molecules in Real Time

The company uses super-resolution microscopy to track the motion of individual proteins within living cells. This technology platform generates up to one petabyte of data every day to help identify and validate new drug targets.

By the Numbers

• Reported zero revenue from product sales for the fiscal year ended December 31, 2025, as all drug candidates remain in the testing phase.
• Maintained a workforce of 384 full-time employees as of December 31, 2025, with 321 staff members dedicated to research and development.
• Operated four distinct drug programs in human clinical trials by the end of 2025, covering various types of solid tumors.
• Held a market capitalization of $30.3 million as of early 2026, reflecting its status as a clinical-stage biotechnology firm.

The Final Word

Eikon has transitioned from a research-focused startup to a clinical-stage organization with multiple cancer treatments in development. The company combines in-licensed assets with internal discovery programs powered by proprietary cell-imaging technology.